Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR5 | Q9H1C0 | 7/20 | 1.00 |
| ▸ | LPAR1 | Q92633 | 14/20 | 0.69 |
| ▸ | LPAR3 | Q9UBY5 | 11/20 | 0.69 |
| ▸ | LPAR2 | Q9HBW0 | 8/20 | 0.61 |
| ▸ | LPAR4 | Q99677 | 6/20 | 0.61 |
| ▸ | LPAR6 | P43657 | 5/20 | 0.61 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | P2RY10 | O00398 | 1/20 | 0.56 |
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL258136 | 1.00 | LPAR5 (1.00) | LPAR5LPAR1LPAR3LPAR2LPAR4 | |
| SCHEMBL7820593 | 1.00 | LPAR5 (1.00) | LPAR5LPAR1LPAR3LPAR2LPAR4 | |
| SCHEMBL28064781 | 1.00 | LPAR5 (1.00) | LPAR5LPAR1LPAR3LPAR2LPAR4 | |
| SCHEMBL26603866 | 1.00 | LPAR5 (1.00) | LPAR5LPAR1LPAR3LPAR2LPAR4 | |
| SCHEMBL258118 | 1.00 | LPAR5 (1.00) | LPAR5LPAR1LPAR3LPAR2LPAR4 | |
| SCHEMBL12621099 | 1.00 | LPAR5 (1.00) | LPAR5LPAR1LPAR3LPAR2LPAR4 | |
| SCHEMBL7829804 | 1.00 | LPAR5 (1.00) | LPAR5LPAR1LPAR3LPAR2LPAR4 | |
| SCHEMBL258161 | 1.00 | LPAR5 (1.00) | LPAR5LPAR1LPAR3LPAR2LPAR4 | |
| SCHEMBL258094 | 1.00 | LPAR5 (1.00) | LPAR5LPAR1LPAR3LPAR2LPAR4 | |
| SCHEMBL250888 | 0.98 | LPAR5 (0.97) | LPAR5LPAR1LPAR3LPAR2LPAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110464709-A | For treating the neuroprotective liposome composition and method of apoplexy | UNIV TEXAS | 2019-11-19 | — | — | CN | claimed |
| CN-105637081-B | Method for forming lipid bilayer on biochip | 吉尼亚科技公司 | 2018-06-01 | — | — | CN | claimed |
| CN-107106708-A | MRI Imaging of Amyloid Plaques Using Liposomes | 德克萨斯州儿童医院 | 2017-08-29 | — | — | CN | claimed |
| CN-117615752-A | RNA compositions comprising buffer substances and methods of making, storing, and using the same | 生物技术欧洲股份公司 | 2024-02-27 | — | — | CN | disclosed |
| CN-110464709-A | For treating the neuroprotective liposome composition and method of apoplexy | UNIV TEXAS | 2019-11-19 | — | — | CN | disclosed |
| CN-110114068-A | Lipid particle composition and medical composition | 富士胶片株式会社 | 2019-08-09 | — | — | CN | disclosed |
| CN-109999013-A | Inhalable dry powder doses | 普马特里克斯营业公司 | 2019-07-12 | — | — | CN | disclosed |
| CN-109937046-A | Liposome anticancer composition | 艾利西斯股份有限公司 | 2019-06-25 | — | — | CN | disclosed |
| CN-109477071-A | The 3D printing of cellularised bracket | 牛津大学创新有限公司 | 2019-03-15 | — | — | CN | disclosed |
| CN-105142681-B | Semi-fluorocarbon containing contrast agents | 贝朗医疗有限公司 | 2019-03-12 | — | — | CN | disclosed |
| CN-109415723-A | IMPROVED PROMOTERS AND COMPOSITIONS | 牛津大学创新有限公司 | 2019-03-01 | — | — | CN | disclosed |
| US-20080234390-A1 | SKIN PORE MINIMIZERS AND SKIN ELASTICITY IMPROVERS | KAO CORPORATION (JP) | 2008-09-25 | — | — | US | disclosed |
| US-20040009140-A1 | Skin pore minimizers and skin elasticity improvers | KAO CORPORATION (JP) | 2004-01-15 | — | — | US | disclosed |
| EP-1325737-A1 | SKIN PORE MINIMIZERS AND SKIN ELASTICITY IMPROVERS | Kao Corporation (JP) | 2003-07-09 | — | — | EP | disclosed |
| EP-1133287-A2 | USE OF 17-KETOSTEROIDS FOR THE TREATMENT OF HEPATITIS C VIRUS AND OTHER TOGAVIRUSES | Hollis-Eden Pharmaceuticals Inc. (US) | 2001-09-19 | — | — | EP | disclosed |
| WO-2000035472-A2 | CYTOKINE COMBINATION THERAPY | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2000-06-22 | — | — | WO | disclosed |
| WO-2000032177-A2 | USE OF 17-KETOSTEROIDS IN THE TREATMENT OF HEPATITIS C VIRUS AND OTHER TOGAVIRUS INFECTIONS | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2000-06-08 | — | — | WO | disclosed |
| WO-1998047516-A1 | COMBINATION THERAPY UTILISING 17-KETOSTEROIDS AND INTERLEUKIN INHIBITORS, OR INTERLEUKIN-10 POTIONALLY WITH INTERLEUKIN INHIBITORS | PRENDERGAST PATRICK T (IE) | 1998-10-29 | — | — | WO | disclosed |
| US-5804552-A | COMPOUND CONSISTING OF TYROSINE OR HYDROXYPROLINE LINKED TO PHOSPHOLIPID BY PHOSPHOESTER BOND THROUGH HYDROXYL GROUP; CAPABLE OF CONJUGATION WITH THERAPEUTIC PEPTIDE | NEXSTAR PHARMACEUTICALS, INC. (US) | 1998-09-08 | — | — | US | disclosed |
| US-5554728-A | Lipid conjugates of therapeutic peptides and protease inhibitors | NEXSTAR PHARMACEUTICALS, INC. (US) | 1996-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009140-A1 | Skin pore minimizers and skin elasticity improvers | CUTA, DSG1, OGA | LPAR5 115/4885LPAR1 26/4885LPAR3 77/4885 |
| US-20080234390-A1 | SKIN PORE MINIMIZERS AND SKIN ELASTICITY IMPROVERS | DSG1, CUTA, OGA | LPAR5 265/4885LPAR1 43/4885LPAR3 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.